GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » Debt-to-EBITDA

NanoString Technologies (NanoString Technologies) Debt-to-EBITDA : -1.96 (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NanoString Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $5.6 Mil. NanoString Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $242.1 Mil. NanoString Technologies's annualized EBITDA for the quarter that ended in Sep. 2023 was $-126.3 Mil. NanoString Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -1.96.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NanoString Technologies's Debt-to-EBITDA or its related term are showing as below:

NSTGQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.19   Med: -1.34   Max: -0.68
Current: -1.72

During the past 13 years, the highest Debt-to-EBITDA Ratio of NanoString Technologies was -0.68. The lowest was -4.19. And the median was -1.34.

NSTGQ's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs NSTGQ: -1.72

NanoString Technologies Debt-to-EBITDA Historical Data

The historical data trend for NanoString Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoString Technologies Debt-to-EBITDA Chart

NanoString Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.89 -4.19 -2.29 -2.48 -1.75

NanoString Technologies Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.90 -1.60 -1.75 -1.65 -1.96

Competitive Comparison of NanoString Technologies's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, NanoString Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoString Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoString Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NanoString Technologies's Debt-to-EBITDA falls into.



NanoString Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NanoString Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.518 + 244.984) / -143.575
=-1.74

NanoString Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.578 + 242.124) / -126.284
=-1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


NanoString Technologies  (OTCPK:NSTGQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


NanoString Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NanoString Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoString Technologies (NanoString Technologies) Business Description

Traded in Other Exchanges
Address
530 Fairview Avenue North, Seattle, WA, USA, 98109
NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.
Executives
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey officer: Chief Financial Officer 1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray director, officer: President and CEO 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr director, 10 percent owner 11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem officer: SVP, Research & Development 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace officer: Chief Commercial Officer C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown officer: SVP, Sales & Marketing 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Janet George director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109